Advertisement
Original article| Volume 33, ISSUE 5, P367-372, March 01, 1993

Platelet serotonin-2 receptors in obsessive-compulsive disorder

  • Subhash C. Pandey
    Affiliations
    Illinois State Psychiatric Institute and College of Medicine, University of Illinois Chicago,Illinois, USA

    Hennepin CountY Medical Center, Minneapolis, Minnesota, USA
    Search for articles by this author
  • Suck Won Kim
    Affiliations
    Illinois State Psychiatric Institute and College of Medicine, University of Illinois Chicago,Illinois, USA

    Hennepin CountY Medical Center, Minneapolis, Minnesota, USA
    Search for articles by this author
  • John M. Davis
    Affiliations
    Illinois State Psychiatric Institute and College of Medicine, University of Illinois Chicago,Illinois, USA

    Hennepin CountY Medical Center, Minneapolis, Minnesota, USA
    Search for articles by this author
  • Ghanshyam N. Pandey
    Correspondence
    Address reprint requests to Ghanshyam N. Pandey, Ph.D., Illinois State Psychiatric Institute, 1153 North Lavergne Avenue, Chicago, IL 60651, USA
    Affiliations
    Illinois State Psychiatric Institute and College of Medicine, University of Illinois Chicago,Illinois, USA

    Hennepin CountY Medical Center, Minneapolis, Minnesota, USA
    Search for articles by this author
DOI:https://doi.org/10.1016/0006-3223(93)90326-9
Platelet serotonin-2 receptors in obsessive-compulsive disorder
Previous ArticleEffects of gender and social isolation on electroencephalogram and neuroendocrine parameters in rats
Next ArticleSerotonin uptake inhibition by the monoamine oxidase inhibitor brofaromine
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      To examine the role of serotonin-2 (5-HT2) receptors in obsessive-compulsive disorder (OCD), we studied 5-HT2 receptors in platelets obtained from patients with OCD (n = 20) during a drug free baseline period, as well as in normal control subjects (n = 25). The maximum number of binding sites (Bmax) and the apparent dissociation constant (Kd) of 5-HT2 receptors were determined by receptor binding techniques using 125I-lysergic acid diethylamide (LSD) as radioligand. We observed that the mean Bmax of 125I-LSD binding in platelets of patients with OCD was not significantly different when compared with normal control subjects. There was also no significant difference in Kd values between patients with OCD and normal control subjects. To examine whether the baseline 5-HT2 receptors are related to the severity of illness, we determined the relationships of the baseline Bmax and Kd with baseline scores of the Hamilton Depression Rating Scale (HDRS), the Yale-Brown Obsessive-Copullsive Scale (Y-BOCS), and the National Institute of Mental Health (NIMH) Obsessive-Compulsive scale (GOCS). We found no significant correlation betwwen baseline Bmax and Kd with the baseline HDRS, Y-BOCS, or NIMH-GOCS scores. Our results do not indicate abnormal 5-HT2 receptors in platelets of patients with OCD.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Arora R.C.
        • Meltzer H.Y.
        Increased serotonin-2 (5-HT2) receptor binding as measured by (3H)-lysergic acid diethylamide (3H-LSD) in the blood-platelets of depressed patients.
        Life Sci. 1989; 44: 725-734
        • Bastani B.
        • Nash J.F.
        • Meltzer H.Y.
        Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessive-compulsive disorder.
        Arch Gen Psychiatry. 1990; 47: 833-839
        • Bastani B.
        • Arora R.C.
        • Meltzer H.Y.
        Serotonin uptake and imipramine binding in the blood and platelets of obsessive-compulsive disorder patients.
        Biol Psychiatry. 1991; 30: 131-139
        • Biegon A.
        • Weizman A.
        • Karp L.
        • Ram A.
        • Tiano S.
        • Wolff M.
        Serotonin 5-HT2 receptor binding on blood platelets: a peripheral marker for depression?.
        Life Sci. 1987; 41: 2485-2492
        • Biegon A.
        • Grinspoon A.
        • Blumenfelt B.
        • Bleich A.
        • Apter A.
        • Mester R.
        Increased serotonin 5-HT2 receptor binding on blood platelets of suicidal men.
        Psychopharmacology. 1990; 100: 165-167
        • Black D.W.
        • Kelly M.
        • Myers C.
        • Noyes R.
        Tritiated imipramine binding in obsessive-compulsive volunteers and psychiatrically normal controls.
        Biol Psychiatry. 1990; 27: 319-327
        • Charney D.S.
        • Goodman W.K.
        • Price L.H.
        • Woods S.W.
        • Rasmussen S.A.
        • Heninger G.R.
        Serotonin function in obsessive compulsive disorder: a comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects.
        Arch Gen Psychiatry. 1988; 45: 177-185
        • Conn P.J.
        • Sanders-Bush E.
        Regulation of serotonin-stimulated phosphoinositide hydrolysis: relation to the serotonin 5HT-2 binding sites.
        J Neurosci. 1986; 6: 3669-3675
        • Cowen P.J.
        • Charig E.M.
        • Fraser S.
        • Elliott J.M.
        Platelet 5-HT receptor binding during depressive illness and tricyclic antidepressant treatment.
        J Affect Disord. 1987; 13: 45-50
        • DeChaffoy deCourcelles D.
        • Leysen J.E.
        • DeClerck F.
        • Vanbelle H.
        • Janssen P.
        Evidence that phospholipid turnover is the signal transducing system coupled to serotonin-S2 receptor sites.
        J Biol Chem. 1985; 260: 7603-7608
        • DeChaffoy deCourcelles D.
        • Roevens P.
        • Wynants J.
        • Vanbelle H.
        Serotonin-induced alterations in inositol phospholipid metabolism in human platelets.
        Biochim Biophys Acta. 1987; 927: 291-302
        • Elliot J.M.
        • Kent A.
        Comparison of [125I]Iodolysergic acid diethylamide binding in human frontal cortex and platelet tissue.
        J Neurochem. 1989; 53: 191-196
        • Flament M.F.
        • Rapoport J.L.
        • Berg C.J.
        • et al.
        Clomipramine treatment of childhood obsessive compulsive disorder: a doubleblind controlled study.
        Arch Gen Psychiatry. 1985; 42: 977-983
        • Geaney D.P.
        • Schachter M.
        • Elliott J.M.
        • Grahame-Smith D.G.
        Characterization of [3H]-lysergic acid diethylamide binding to a 5-hydroxytryptamine receptor on human platelet membranes.
        Eur J Pharmacol. 1984; 97: 87-93
        • Goodman W.K.
        • Price L.
        • Rasmussen S.A.
        • et al.
        The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): Part I. Development, use and reliability.
        Arch Gen Psychiatry. 1989; 46: 1006-1011
        • Goodman W.K.
        • Price L.
        • Rasmussen S.A.
        • et al.
        The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): Part II. Validity.
        Arch Gen Psychiatry. 1989; 46: 1012-1216
        • Hamik A.
        • Peroutka S.J.
        I-(m-chlorophenyl) piperazine (m-CPP) interactions with neurotransmitter receptors in the human brain.
        Biol Psychiatry. 1989; 25: 569-575
        • Hamilton M.
        A rating scale for depression.
        J Neurol Neurosurg Psychiatry. 1960; 3: 56-62
        • Hollander E.
        • Fay M.
        • Cohen B.
        • Campeas R.
        • Gorman J.M.
        • Liebowitz M.R.
        Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findings.
        Am J Psychiatry. 1988; 145: 1015-1017
        • Hollander E.
        • Decaria C.M.
        • Nitesu A.
        • et al.
        Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers.
        Arch Gen Psychiatry. 1992; 49: 21-28
        • Hoyer D.
        Functional correlates of serotonin 5-HT-1 recognition sites.
        J Recept Res. 1988; 8: 59-81
        • Insel T.R.
        • Mueller E.A.
        • Alterman I.
        • Linnoila M.
        • Murphy D.L.
        Obsessive compulsive disorder and serotonin: is there a connection?.
        Biol Psychiatry. 1985; 20: 1174-1188
        • Kim S.W.
        • Dysken M.W.
        • Pandey G.N.
        • Davis J.M.
        Platelet 3H-imipramine binding sites in obsessive compulsive behavior.
        Biol Psychiatry. 1991; 30: 467-474
        • Lesch K.P.
        • Hoh A.
        • DisselKamp-Tietze J.
        • Wiesmann M.
        • Osterheider M.
        • Schulte H.M.
        5-Hydroxytryptamine1A receptor responsivity in obsessive-compulsive disorder: comparison of patients and controls.
        Arch Gen Psychiatry. 1991; 48: 540-547
        • Lowry O.H.
        • Rosenbrough N.J.
        • Farr A.L.
        • Randall R.J.
        Protein measurement with the folin phenol reagent.
        J Biol Chem. 1951; 193: 265-275
        • Mann J.J.
        • Stanley M.
        • McBride P.A.
        • McEwen B.S.
        Increased serotonin2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims.
        Arch Gen Psychiatry. 1986; 43: 945-959
        • McBride P.A.
        • Mann J.J.
        • Polley J.J.
        • Wiley A.J.
        • Sweeney J.A.
        Assessment of binding indices and physiological responsiveness of the 5-HT2 receptor on human platelets.
        Life Sci. 1987; 40: 1799-1809
        • McPherson G.A.
        Analysis of radioligand binding experiments: a collection of computer programs for the IBM PC.
        J Pharmacol Methods. 1985; 14: 213-228
        • Murphy D.L.
        • Pickar D.
        • Alterman I.S.
        Methods for the quantitative assessment of depressive and manic behavior.
        in: Burdock E.L. Sudilovsky A. Gershon S. The Behavior of Psychiatric Patients. Marcel Deker, New York1982: 355-392
        • Murphy D.L.
        • Zohar J.
        • Benkelfat C.
        • Pato M.T.
        • Pigott T.A.
        • Insel T.R.
        Obsessive-compulsive disorder as a serotonin subsystem-related behavioral disorder.
        Br J Psychiatry. 1989; 155: 15-24
        • Pandey G.N.
        • Pandey S.C.
        • Janicak P.G.
        • Marks R.C.
        • Davis J.M.
        Platelet serotonin-2 receptor binding sites in depression and suicide.
        Biol Psychiatry. 1990; 28: 215-222
        • Peters J.R.
        • Grahame-Smith D.G.
        Human platelet 5HT2 receptors: characterization and functional associations.
        Eur J Pharmacol. 1980; 68: 243-256
        • Pigott T.A.
        • Johar J.
        • Hill J.L.
        • et al.
        Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenyl piperazine in patients with obsessive-compulsive disorder.
        Biol Psychiatry. 1991; 29: 418-426
        • Price L.H.
        • Goodman W.K.
        • Charney D.S.
        • Rasmussen S.A.
        • Heninger G.R.
        Treatment of severe obsessive-compulsive disorder with fluvoxamine.
        Am J Psychiatry. 1987; 144: 1059-1061
        • Stanley M.
        • Mann J.J.
        Increased serotonin-2 binding sites in frontal cortex of suicide victims.
        Lancet. 1983; i: 214-216
        • Thoren P.
        • Asberg M.
        • Cronholm B.
        • Jornestedt L.
        • Traskman L.
        Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial.
        Arch Gen Psychiatry. 1980; 37: 1281-1285
        • Thoren P.
        • Asberg M.
        • Bertilsson L.
        • Mellstrom B.
        • Sjogrist F.
        • Traskmann L.
        Clomipramine treatment of obsessive compulsive disorder. II. Biochemical aspects.
        Arch Gen Psychiatry. 1980; 37: 1289-1294
        • Turner S.M.
        • Jacob R.G.
        • Beidel D.C.
        • Himmelhoch J.
        Fluoxetine treatment of obsessive-compulsive disorder.
        J Clin Psychopharmacol. 1985; 5: 207-212
        • Vitiello B.
        • Shimon H.
        • Behar D.
        • Stoff D.
        • Bridger W.H.
        • Friedman E.
        Platelet imipramine binding and serotonin uptake in obsessive compulsive patients.
        Acta Psychiatr Scand. 1991; 84: 29-32
        • Weizman A.
        • Carmi M.
        • Hermesh H.
        • et al.
        High affinity imipramine binding and serotonin uptake in platelets of eight adolescent and ten adult obsessive compulsive patients.
        Am J Psychiatry. 1986; 143: 335-339
        • Zohar J.
        • Kindler S.
        Serotonergic probes in obsessive compulsive disorder.
        Int Clin Psychopharmacol. 1992; 7: 39-40
        • Zohar J.
        • Mueller E.A.
        • Insel T.R.
        • Zohar-Kadouch R.C.
        • Murphy D.L.
        Serotonergic responsivity in obsessive-compulsive disorder. Comparisons of patients and healthy controls.
        Arch Gen Psychiatry. 1987; 44: 946-951

      Article info

      Publication history

      Received in revised form: August 25, 1992
      Received: May 1, 1992

      Footnotes

      ☆This research was supported in part by funds from Pfizer Inc.

      Identification

      DOI: https://doi.org/10.1016/0006-3223(93)90326-9

      Copyright

      © 1993 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX